Literature DB >> 1138397

Effect of various corticosteroids upon the phagocytic bactericidal activity of neutrophils.

M M Fuenfer, G E Olson, H C Polk.   

Abstract

Corticosteroid compounds are used broadly in surgical practice, although mechanisms remain unclarified and efficacy in some situations remains unproved. A recognized adverse effect of steroids in all doses is the potentiation of infection. Specific derivatives of the glucocorticoids appear to have varying degrees of effectiveness in the enhancement of bacterial infection. To evaluate such effects objectively, a series of experiments was undertaken to measure the phagocytic-bactericidal activity of polymorphonuclear leukocytes. This study examines the differential effects of clinical dose equivalents of four glucocorticoid derivatives in depressing in vitro neutrophil phagocytic-bactericidal function. Neutrophils separated from normal human plasma were incubated in vitro in the presence of hydrocortisone sodium phosphate, hydrocortisone sodium succinate, dexamethasone sodium phosphate, and methylprednisolone sodium succinate. Hydrocortisone sodium phosphate, hydrocortisone sodium succinate, and dexamethasone sodium phosphate produce variable, short-term inhibitory effects upon the systems within the neutrophil which are responsible for its bactericidal competency. Methylprednisolone sodium succinate appears to be free of these adverse effects. These in vitro experiments indicate that diminished risk of infection should attend the use of methylprednisolone sodium succinate, although the precise mechanism have not been defined.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1138397

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  11 in total

1.  Perceived efficacy and risks of infection following intra-articular injections: a survey of orthopaedic surgeons.

Authors:  M A Farooq; A T Devitt
Journal:  Ir J Med Sci       Date:  2005 Jan-Mar       Impact factor: 1.568

Review 2.  A review of the use of corticosteroids in the management of pulmonary injuries and insults.

Authors:  C Robertson
Journal:  Arch Emerg Med       Date:  1985-06

3.  Prednisolone inhibits phagocytosis by polymorphonuclear leucocytes via steroid receptor mediated events.

Authors:  C J Jones; K J Morris; M I Jayson
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

4.  In vivo dexamethasone effects on neutrophil effector functions in a rat model of acute lung injury.

Authors:  E C O'Leary; G F Evans; S H Zuckerman
Journal:  Inflammation       Date:  1997-12       Impact factor: 4.092

5.  The effects of prednisolone in leucocyte function in man. A double blind controlled study.

Authors:  J R Clarke; R F Gagnon; F M Gotch; M R Heyworth; I C Maclennan; S C Truelove; C A Waller
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

6.  Treatment of peptic ulcer disease in the renal transplant patient.

Authors:  M L Owens; E Passaro; S E Wilson; H E Gordon
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

7.  The effects on polymorphonuclear leucocyte function of prednisolone and azathioprine in vivo and prednisolone, azathioprine and 6-mercaptopurine in vitro.

Authors:  A Losito; D G Williams; G Cooke; L Harris
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

8.  Factors which influenced postoperative complications in patients with ulcerative colitis or Crohn's disease of the colon on corticosteroids.

Authors:  J R Allsop; E C Lee
Journal:  Gut       Date:  1978-08       Impact factor: 23.059

Review 9.  Metabolic basis for management of the septic surgical patient.

Authors:  J H Shaw; J B Koea
Journal:  World J Surg       Date:  1993 Mar-Apr       Impact factor: 3.352

10.  Inhibition of glucocorticoid-induced alteration of vimentin by a glucocorticoid receptor antagonist RU486 in the organ-cultured rat lens.

Authors:  Guo-Li Xie; Hong Yan; Zi-Fan Lu
Journal:  Mol Vis       Date:  2011-01-06       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.